1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Muscle Spasm - Pipeline Review, H2 2014

Muscle Spasm - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 35 pages

Muscle Spasm - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Muscle Spasm - Pipeline Review, H2 2014’, provides an overview of the Muscle Spasm’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Muscle Spasm, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Spasm and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Muscle Spasm
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Muscle Spasm and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Muscle Spasm products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Muscle Spasm pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Muscle Spasm
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Muscle Spasm pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Muscle Spasm - Pipeline Review, H2 2014
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Muscle Spasm Overview 6
Therapeutics Development 7
Pipeline Products for Muscle Spasm - Overview 7
Pipeline Products for Muscle Spasm - Comparative Analysis 8
Muscle Spasm - Therapeutics under Development by Companies 9
Muscle Spasm - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Muscle Spasm - Products under Development by Companies 12
Muscle Spasm - Companies Involved in Therapeutics Development 13
Eisai Co., Ltd. 13
Omeros Corporation 14
Sanochemia Pharmazeutika AG 15
Muscle Spasm - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 24
(diclofenac sodium + eperisone) - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
(ketoprofen + nifedipine) - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Drug for Neuromuscular Disorders and Muscle Cramps - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
NVP-1102 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
tolperisone - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Muscle Spasm - Recent Pipeline Updates 31
Muscle Spasm - Dormant Projects 32
Muscle Spasm - Product Development Milestones 33
Featured News and Press Releases 33
Nov 23, 2012: Sanochemia Receives US Notice Of Allowance For Manufacture Of Tolperisone 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables

Number of Products under Development for Muscle Spasm, H2 2014 7
Number of Products under Development for Muscle Spasm - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Muscle Spasm - Pipeline by Eisai Co., Ltd., H2 2014 13
Muscle Spasm - Pipeline by Omeros Corporation, H2 2014 14
Muscle Spasm - Pipeline by Sanochemia Pharmazeutika AG, H2 2014 15
Assessment by Monotherapy Products, H2 2014 16
Assessment by Combination Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 23
Muscle Spasm Therapeutics - Recent Pipeline Updates, H2 2014 31
Muscle Spasm - Dormant Projects, H2 2014 32

List of Figures

Number of Products under Development for Muscle Spasm, H2 2014 7
Number of Products under Development for Muscle Spasm - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 11
Assessment by Monotherapy Products, H2 2014 16
Assessment by Combination Products, H2 2014 17
Number of Products by Top 10 Targets, H2 2014 18
Number of Products by Stage and Top 10 Targets, H2 2014 18
Number of Products by Top 10 Mechanism of Actions, H2 2014 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 20
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 22
Number of Products by Stage and Top 10 Molecule Types, H2 2014 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.